The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin

Author： Devine E. B. Cross J. T. Kowdley K. V. Sullivan S. D.

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.6, 2007-06, pp. : 1463-1472

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant Human Erythropoietin in the Treatment of Chronic Anemia of Cancer

Acta Haematologica, Vol. 100, Iss. 2, 1998-10 ,pp. : 115-115

Karger

Access to resources Recommend Favorite

Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia

Oncology Research and Treatment, Vol. 28, Iss. 4, 2005-10 ,pp. : 216-221

Karger

Access to resources Recommend Favorite

Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 9, 2015-09 ,pp. : 813-819

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pure Red Cell Aplasia Induced by Antibodies against Human Recombinant Erythropoietin

Transfusion Medicine and Hemotherapy, Vol. 32, Iss. 2, 2005-04 ,pp. : 97-100

Karger

Access to resources Recommend Favorite

Predicting the Hematopoietic Response to Recombinant Human Erythropoietin (Epoetin Alfa) in the Treatment of the Anemia of Cancer

Oncology, Vol. 56, Iss. 1, 1999-01 ,pp. : 46-53

Karger

Access to resources Recommend Favorite